Cystic Fibrosis (CF) Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Cystic Fibrosis (CF) Treatment Market: By Product Type (Pancreatic enzyme supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration (Oral and Inhaled), and Geography 

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Cystic Fibrosis (CF) Treatment Market size was valued at USD 5040.0 million in 2021 and is expected to reach USD 9332.3 million by 2028, at a CAGR of 9.2% during the forecast period 2022-2028. Cystic fibrosis is a genetic disorder that causes severe damage to secretory glands of body such as lungs, pancreas, liver and intestines. It is more common in lungs. The disease is progressive with several mutations in the genes, which causes cystic fibrosis. In cystic fibrosis, the abnormal secretions from various secretory glands builds mucus which results in improper working of the organ that is affected. The treatment of cystic fibrosis helps loosening mucus which includes physical therapy. There are various therapeutic products available for the treatment of cystic fibrosis, which include enzymes, antibiotics and others. According to CFF’s national patient registry, the median age of the person with cystic fibrosis is currently 33.4 years. Basing on the severity of the disease, cystic fibrosis signs and symptoms vary. The Wide- research on Cystic Fibrosis (CF) resulted in dramatic improvements in the treatment of the disease, which has quadrupled the median life expectancy to 37 years of age in the U.S. In parts of the world where state-of-the-art medical care is not available, life expectancy remains much lower. In Europe, 51.8% were adults with age 18 years or more and 48.2% were less than 18 years old. New therapeutics are currently in development, of which some may provide a functional CFTR protein in patients with some versions of the gene, potentially eliminating many disease complications and allowing people with the disease to live essentially normal lives. Cystic fibrosis is a hereditary disease that mostly affects the lungs, but also affects the pancreas, liver, and kidney. The cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation causes it. This gene, which is found on chromosome 7, is in charge of perspiration, mucus, and bodily fluids regulation. However, a mutation in this gene causes CFTR activity to be absent, resulting in chloride loss and protein structural changes.

Cystic Fibrosis (CF) Treatment Market

MARKET SUMMARY
-
9.2%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 9.2%
  • Largest Market– Asia-Pacific
  • Fastest Growing Market– North-America

Cystic Fibrosis (CF) Treatment Market

  • The global cystic fibrosis treatment market report gives comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report on global cystic fibrosis treatment market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, by route of administration and geographical regions.
Key Players
  • Gilead
  • AbbVie Inc
  • Novartis AG.
  • Hoffmann-La Roche Ltd
  • Alaxia, Merck & Co. Inc.
Cystic Fibrosis (CF) Treatment Market

DRIVERS AND RESTRAINTS

The major factors that are driving cystic fibrosis (CF) treatment market includes, increasing prevalence of the cystic fibrosis, rising awareness among healthcare fraternity about cystic fibrosis therapy. Advancement in the technology, and better healthcare facilities are also some of the factors influencing the cystic fibrosis therapeutics market. However, the cystic fibrosis therapeutics market growth hindering due to high cost of the treatment, increase in complexity of disease. Moreover, patent expiries from many companies and introduction of generic drugs hold back the growth of global cystic fibrosis market


North-America Got Significant Share

Cystic Fibrosis (CF) Treatment Market

Geographically, global Cystic Fibrosis (CF) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America stands for largest revenue share due to huge affected population. However, the underdiagnoses and lack of country-specific CF patient registries, Asia Pacific region would be forecasted for higher growth of the market. The region that falls next to North America is Europe. According to the European Cystic Fibrosis Society (ECFS), more than 35,500 people were suffering from cystic fibrosis in 2014. The Asian region has lesser prevalence rate. Whereas in East Asian countries like China and Japan the disease is rare. The Middle East and Africa holds the least share in the market owing to the lack of healthcare infrastructure, especially countries in the African region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report covers exhaustive regional information, that includes North America (the USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentian, Venezula, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2016-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Cystic Fibrosis (CF) Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

Table of Content
1. Executive Summary
2. Global Cystic Fibrosis Treatment Market Introduction
2.1. Global Cystic Fibrosis Treatment Market – Taxonomy
2.2. Global Cystic Fibrosis Treatment Market –Definitions
2.2.1. By Drug Class
2.2.2. By Route of Administration
2.2.3. By Region
3. Global Cystic Fibrosis Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cystic Fibrosis Treatment Market Dynamic Factors – Impact Analysis
3.6. Global Cystic Fibrosis Treatment Market – Competition Landscape
4. Global Cystic Fibrosis Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Cystic Fibrosis Treatment Market, By Drug Class, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1. Pancreatic enzyme supplements
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Mucolytics
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Bronchodilators
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. CFTR Modulators
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Cystic Fibrosis Treatment Market, By Route of Administration, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1. Oral drugs
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Inhaled drugs
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Cystic Fibrosis Treatment Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Cystic Fibrosis Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, and Region, 2022 – 2028
8. North America Cystic Fibrosis Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Pancreatic enzyme supplements
8.1.2. Mucolytics
8.1.3. Bronchodilators
8.1.4. CFTR Modulators
8.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Oral drugs
8.2.2. Inhaled drugs
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Cystic Fibrosis Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, and Country, 2022 – 2028
8.5. North America Cystic Fibrosis Treatment Market Dynamics – Trends
9. Europe Cystic Fibrosis Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Pancreatic enzyme supplements
9.1.2. Mucolytics
9.1.3. Bronchodilators
9.1.4. CFTR Modulators
9.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oral drugs
9.2.2. Inhaled drugs
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Europe Cystic Fibrosis Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, and Country, 2022 – 2028
9.5. Europe Cystic Fibrosis Treatment Market Dynamics – Trends
10. Asia-Pacific Cystic Fibrosis Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Pancreatic enzyme supplements
10.1.2. Mucolytics
10.1.3. Bronchodilators
10.1.4. CFTR Modulators
10.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oral drugs
10.2.2. Inhaled drugs
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Cystic Fibrosis Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, and Country, 2022 – 2028
10.5. Asia-Pacific Cystic Fibrosis Treatment Market Dynamics – Trends
11. Latin America Cystic Fibrosis Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Pancreatic enzyme supplements
11.1.2. Mucolytics
11.1.3. Bronchodilators
11.1.4. CFTR Modulators
11.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oral drugs
11.2.2. Inhaled drugs
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Cystic Fibrosis Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, and Country, 2022 – 2028
11.5. Latin America Cystic Fibrosis Treatment Market Dynamics – Trends
12. Middle East and Africa Cystic Fibrosis Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Pancreatic enzyme supplements
12.1.2. Mucolytics
12.1.3. Bronchodilators
12.1.4. CFTR Modulators
12.2. Route of Administration Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oral drugs
12.2.2. Inhaled drugs
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Cystic Fibrosis Treatment Market – Opportunity Analysis Index, By Drug Class, Route of Administration, and Country, 2022 – 2028
12.5. MEA Cystic Fibrosis Treatment Market Dynamics – Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Drug Class Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Abbvie Inc.
13.2.2. Alaxia
13.2.3. Allergan
13.2.4. Alcresta Therapeutics Inc.
13.2.5. AstraZeneca
13.2.6. F. Hoffmann-La Roche Ltd
13.2.7. Gilead Sciences Inc.
13.2.8. Merck & Co., Inc.
13.2.9. Novartis AG
13.2.10. Teva Pharmaceutical Industries Ltd.
13.2.11. Vertex Pharmaceuticals Inc.
13.2.12. Chiesi Farmaceutici SpA
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • Vertex Pharmaceuticals Incorporated,
  • Gilead
  • AbbVie Inc
  • Novartis AG.
  • Hoffmann-La Roche Ltd
  • Alaxia, Merck & Co. Inc.
  • AIT (Advanced Inhalation Therapies)
  • ALLERGAN plc
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd.
  • Alcresta Therapeutics, Inc.
  • Chiesi FarmaceuticiSpA

Description

Cystic Fibrosis (CF) Treatment Market size was valued at USD 5040.0 million in 2021 and is expected to reach USD 9332.3 million by 2028, at a CAGR of 9.2% during the forecast period 2022-2028. Cystic fibrosis is a genetic disorder that causes severe damage to secretory glands of body such as lungs, pancreas, liver and intestines. It is more common in lungs. The disease is progressive with several mutations in the genes, which causes cystic fibrosis. In cystic fibrosis, the abnormal secretions from various secretory glands builds mucus which results in improper working of the organ that is affected. The treatment of cystic fibrosis helps loosening mucus which includes physical therapy. There are various therapeutic products available for the treatment of cystic fibrosis, which include enzymes, antibiotics and others. According to CFF’s national patient registry, the median age of the person with cystic fibrosis is currently 33.4 years. Basing on the severity of the disease, cystic fibrosis signs and symptoms vary. The Wide- research on Cystic Fibrosis (CF) resulted in dramatic improvements in the treatment of the disease, which has quadrupled the median life expectancy to 37 years of age in the U.S. In parts of the world where state-of-the-art medical care is not available, life expectancy remains much lower. In Europe, 51.8% were adults with age 18 years or more and 48.2% were less than 18 years old. New therapeutics are currently in development, of which some may provide a functional CFTR protein in patients with some versions of the gene, potentially eliminating many disease complications and allowing people with the disease to live essentially normal lives. Cystic fibrosis is a hereditary disease that mostly affects the lungs, but also affects the pancreas, liver, and kidney. The cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation causes it. This gene, which is found on chromosome 7, is in charge of perspiration, mucus, and bodily fluids regulation. However, a mutation in this gene causes CFTR activity to be absent, resulting in chloride loss and protein structural changes.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX